Alteogen Inc 196170
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
-
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
Trading Information
- Previous Close Price
- ₩265,000.00
- Day Range
- ₩257,000.00–268,000.00
- 52-Week Range
- ₩194,615.38–437,692.31
- Bid/Ask
- ₩259,000.00 / ₩259,500.00
- Shares Outstanding
- 69.56M
- Market Cap
- ₩18.05T
- Volume/Avg
- 234,723 / 550,958
Key Statistics
- Price/Earnings (Normalized)
- 80.86
- Price/Sales
- 72.09
- Dividend Yield (Trailing)
- 0.11%
- Dividend Yield (Forward)
- 0.11%
- Dividend Payment Schedule
- Apr
- Total Yield
- 0.11%
Company Profile
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 157
- Website
- https://www.alteogen.com
Valuation
|
Metric
|
196170
|
|---|---|
Price/Earnings (Normalized) | 80.86 |
Price/Book Value | 34.32 |
Price/Sales | 72.09 |
Price/Cash Flow | 187.43 |
Price/Earnings
196170
Financial Strength
|
Metric
|
196170
|
|---|---|
Quick Ratio | 2.69 |
Current Ratio | 2.76 |
Interest Coverage | 15.88 |
Quick Ratio
196170
Profitability
|
Metric
|
196170
|
|---|---|
Return on Assets (Normalized) | 25.59% |
Return on Equity (Normalized) | 40.19% |
Return on Invested Capital (Normalized) | 38.16% |
Return on Assets
196170
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Q>YT>M | LOCK|m?jr | $128B | |||
| Moderna Inc
MRNA
| LOCK|#z$m^jZ | LOCK|?#y | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$^PZR## | LOCK|bKv> | $76B | |||
| argenx SE ADR
ARGX
| LOCK|!XL^>B | LOCK|gW | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|K?pD>M | LOCK|zp^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|j>%gZ% | LOCK|%hfjt | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|><#q#vB | LOCK|#@M^ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Kl^dn?> | LOCK|<!H | $24B | |||
| Incyte Corp
INCY
| LOCK|!$%rs?p | LOCK|Wc | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^!!fWz! | LOCK|?l | $15B |
United States